H.C. Wainwright lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $19 from $22 and keeps a Buy rating on the shares. The firm remove ACR-368 sales for bladder cancer and shifted its ovarian cancer sales to ACR-2316 “given ovarian cancer is a clinically de-risked indication for WEE1 inhibitors.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics, Inc. (ACRV) Q4 Earnings Cheat Sheet
- Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating
- Acrivon Therapeutics Appoints New Chief Financial Officer
- Acrivon Therapeutics announces FDA granted BDD for ACR-368
- Acrivon Therapeutics initiated with an Overweight at Cantor Fitzgerald